– Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced a collaboration with the Center for Immunotherapy and Precision
Immuno-Oncology (CITI) and the Cleveland Clinic Lerner Research Institute, Cleveland, Ohio. Both parties will collaborate to enhance capabilities within elioTM plasma complete reporting, as well as collaborate on the development of proprietary methods for complex biomarker detection and assay
iterations to meet emerging liquid biopsy applications in solid tumors.
This strategic collaborationcombines Cleveland Clinic’s world-class research and commitment to innovation with the comprehensive PGDx portfolio and actionable genomic information. Both organizations are driven to elevate the standard of care for patients and increase utilization of precision diagnostics within the cancer care continuum.
“We are thrilled to collaborate with Cleveland Clinic, whose dedication to empowering the best care and research possible for patients with cancer, along with an immense track record of superior outcomes, makes them an ideal partner in this venture,” said PGDx CEO Megan Bailey. “We look forward to expanding upon the capabilities of elioTM plasma complete and paving the way for a Center of Excellence enabling enhanced testing of ctDNA in cancer.”
The CITI ctDNA team will work closely with the Cleveland Clinic Taussig Cancer Institute and the Pathology and Laboratory Medicine Institute to accelerate progress in ctDNA work in cancer patients. This effort is a partnership with Jame Abraham, M.D., Interim Chair, Cleveland Clinic Taussig Cancer
Institute and Brian Rubin, M.D., Chairman of the Pathology and Laboratory Medicine Institute at Cleveland Clinic.
Timothy Chan, M.D., Ph.D., Chair of Cleveland Clinic’s Center for Immunotherapy & Precision ImmunoOncology, said “This collaboration allows us to continue exploring new options to improve treatment strategies and patient outcomes in cancer. By investing in comprehensive testing solutions that utilize
non-invasive sampling techniques, we intend to explore the clinical utility of high impact biomarkers such as blood TMB, clonal hematopoiesis, and others, with the aim to improve therapeutic modalities for human cancers.”